Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-03-14

Tempus AI, Inc.

Tempus sells molecular diagnostics, data licensing, and AI-enabled clinical software to physicians, health systems, and life sciences companies.

ai biotech healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated data moat, not pure AI software

The core question is whether a fast-growing diagnostics platform can convert scale into a more durable data and workflow business before valuation patience runs out. The upside is real, but it depends on monetizing trust, reimbursement, and integration rather than just shipping AI features.

Analysis

Thesis

Tempus can turn diagnostics scale into a governed clinical-data and workflow moat: if oncology, hereditary, and monitoring volume keep compounding while data and applications become a larger mix, the business can outgrow diagnostics peers and still merit a premium multiple even without pure-software economics.

Last Economy Alignment

Tempus benefits as AI makes multimodal clinical data and embedded workflows more valuable, but value capture is still gated by reimbursement, regulation, and clinical trust.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.9x (from 5 most recent analyses)

Reasoning

The upside comes from mix shift, not just more tests. If diagnostics volume keeps feeding a higher-margin data, applications, and workflow layer, the market can still pay a premium growth multiple even after some AI-halo normalization. I underwrite meaningful growth plus moderate multiple compression from current enthusiasm, which still supports a solid double over five years.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risks are external gates, not product existence: reimbursement, FDA and update pathways, and proof that acquired assets become durable margin improvement. If Q1-Q2 2026 cadence weakens or AI applications fail to monetize beyond test pull-through, the stock can de-rate even with continued revenue growth.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No clearly material company release surfaced in the last 7-10 days after the February 24, 2026 results package; the thesis still rests on that update.
The fresh operating anchor remains FY2026 guidance for 1590 revenue and about 65 adjusted EBITDA.
Near-term debate has narrowed to Q1 cadence, monitoring-test volume follow-through, and whether integration benefits show in margins by mid-2026.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.62

They control hard-to-get clinical data connections and regulated tests, so cheaper AI makes their dataset and workflows more useful over time. The risk is that payers and regulators, not software engineers, still decide how fast that value turns into profits.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$78.20

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research